New Viking Therapeutics (NASDAQ:VKTX)’s Coverage By Raymond James with $15 Target.

June 29, 2018 - By Don Salinas

Viking Therapeutics, Inc. (NASDAQ:VKTX) Corporate Logo

What Price Target Has Raymond James Given Viking Therapeutics (NASDAQ:VKTX)

After Raymond James’s $15 target price per share was issued to clients and investors on Thursday, 28 June, the company has started coverage of the Viking Therapeutics (NASDAQ:VKTX)‘s stock. The broker set a “Outperform” rating of VKTX.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Coverage

In total 5 analysts cover Viking Therapeutics (NASDAQ:VKTX). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. (NASDAQ:VKTX) has 100% bullish analysts. 6 are the (NASDAQ:VKTX)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Friday, June 1 the firm earned “Buy” rating by Maxim Group. On Friday, June 1 the company was maintained by H.C. Wainwright. In Monday, March 26 report H.C. Wainwright reinitiated the stock with “Buy” rating. On Thursday, March 8 the firm earned “Buy” rating by Roth Capital.

VKTX reached $9.5343 during the last trading session after $0.2457 change.Viking Therapeutics, Inc. has volume of 1.31 million shares. Since June 29, 2017 VKTX has risen 320.16% and is uptrending. VKTX outperformed the S&P 500 by 307.59%.

On August, 8 WallStreet awaited Viking Therapeutics, Inc. (NASDAQ:VKTX)’s earnings report, according to Zacks. Analysts expect change of 42.86 % or $0.09 from previous year’s $-0.21 earnings per share compared to current’s $-0.12 earnings per share. 20.00 % negative EPS growth is what analysts predict. $-0.10 earnings per share was reported for last quarter.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.The firm is worth $567.85 million. The Company’s lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.Last it reported negative earnings. The firm is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia.

For more Viking Therapeutics, Inc. (NASDAQ:VKTX) news brought out recently go to: Fool.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Fool.com. The titles are as follows: “Viking Therapeutics, Buy the Dip?” brought out on June 26, 2018, “Viking Therapeutics: Hallmark Moment” on June 13, 2018, “Viking Therapeutics: Sell The Pop On The Sympathy Play” with a publish date: June 01, 2018, “Viking Therapeutics: What Now After ‘Yuge’ Rally?” and the last “Why Viking Therapeutics Stock Is On Fire Today” with publication date: May 31, 2018.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.